Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

Post to Reddit

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Selected as a Featured Poster and ACR’s Ignite Talk is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy,” part of the core technology powering Exagen’s AVISE® RADR test development. In addition, data from Exagen’s research on machine learning in patients with fibromyalgia has been accepted for an oral presentation.

Exagen’s President and Chief Executive Officer, Ron Rocca, shared, “Exagen is honored to have nine scientific abstracts accepted for ACR’s 2022 annual conference, with a featured poster focusing on AVISE® RADR and a podium presentation. We continue to assist physicians by adding clarity to their clinical diagnoses by providing precision testing; we believe good science leads to good decisions.”

Below is the list of accepted abstracts, with links to each:

Saturday, November 12, 2022

Poster Presentation | Presented by Geoffrey Stephens, PhD | Abstract #0324
Title: Comparison of nCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
Session Time: 1:00 – 3:00pm ET

Sunday, November 13, 2022

Featured Poster Presentation | Presented by Giorgio Casaburi, PhD | Abstract #0935
Title: Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Session Title: RA – Treatment Poster II
Session Time: 9:00 – 10:30am ET

Poster Presentation | Presented by Anca Askanase, MD | Abstract #1442
Title: Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations
Session Time: 1:00 – 3:00pm ET

Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1221
Title: Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Session Title: Fibromyalgia and Other Clinical Pain Syndromes Poster
Session Time: 1:00 – 3:00pm ET

Poster Presentation | Presented by Emily G Oaks | Abstract #1201
Title: Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms after COVID-19 Infection
Session Title: Epidemiology and Public Health Poster II
Session Time: 1:00 – 3:00pm ET

Monday, November 14, 2022

Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1762
Title: Stability of Cell Bound Complement Activation Products (CB-CAPS), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-COV-2 Pandemic and Vaccination Campaigns
Session Title: Epidemiology and Public Health Poster III
Session Time: 1:00 – 3:00pm ET

Poster Presentation | Presented by Giorgio Casaburi, PhD | Abstract #1990
Title: Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients who will Respond or be Refractory to Standard Biological Treatments
Session Title: RA – Treatment Poster IV
Session Time: 1:00 – 3:00pm ET

Poster Presentation | Presented by Jennifer Rogers, MD | Abstract #2104
Title: The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE.
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes
Session Time: 1:00 – 3:00pm ET

Oral Presentation | Presented by Geoffrey Stephens, PhD | Abstract #2233
Title: Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia
Session Title: Abstracts: Fibromyalgia and Other Clinical Pain Syndromes
Session Time: 4:30 – 5:30pm ET

About Exagen Inc.

Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development team’s scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products or promoted therapeutics, including Exagen’s ability to collect funds due; expectations regarding its pipeline products, including the development of the AVISE® RADR platform; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com 
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com 
760.477.5514


View source version on GlobeNewswire.com